Certis Oncology to Present at the 9th Annual Tumor Models San Francisco Summit
Presentation to highlight the power of CertisAI™ and CertisOI Assistant™ in tumor model selection and predictive insights for drug discovery.
San Diego, Calif. — January 28, 2025 – Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine announced its participation in the Tumor Models San Francisco, taking place January 29-30th, 2025. Certis will share its innovative approach to accelerating drug development through the integration of artificial intelligence (AI), advanced imaging, and highly characterized patient-derived xenograft (PDX) models.
Attendees are invited to join Michael Boice’s presentation, “Leveraging Genomic, Clinical, and Drug Response Data in the Age of AI,” which will address the evolving role of tumor model characterization data in drug development decision-making. Topics will include:
- Leveraging predictive AI to conduct in silico analysis of tumor data, uncovering insights into therapeutic efficacy and drug response.
- Exploring advances in generative AI that streamline data retrieval and empower research teams to conduct ad hoc analyses.
- Demonstrating how tumor characterization data supports informed decision-making throughout preclinical research and clinical translation.
- Showcasing how to use CertisOI Assistant™ to explore models, generate predictions, and visualize results.
CertisOI Assistant™ integrates the power of BarneyOI® and CertisAI™ to provide an intuitive, AI-driven platform that enhances research workflows. By merging these two technologies, Certis OI Assistant™ enables drug developers to efficiently explore tumor models, generate predictive insights, and visualize results. A developer from Certis will be present onsite to demonstrate the platform, answer questions, and provide insights into how the tool supports oncology research optimization.
“We believe that the future of drug development lies in the ability to harness AI to not only optimize the exploration of tumor models, but to also provide actionable insights that can significantly improve the efficacy of oncology treatments,” said Peter Ellman, CEO of Certis Oncology. “Certis OI Assistant™ embodies this vision, empowering researchers to make faster, more informed decisions that will drive better patient outcomes.”
A free version of the CertisOI Assistant is now available to cancer researchers worldwide and can be accessed online.
About CertisAI™
CertisAI™ is a patent-pending predictive artificial intelligence/machine learning (AI/ML) platform developed by Certis Oncology Solutions. It is the first and only commercially available, validated AI/ML platform that predicts therapeutic efficacy by identifying complex gene expression signatures that correlate with drug response. The platform is designed to assist pharmaceutical researchers to develop and clinicians to identify new treatment options for specific cancers based on a tumor’s unique gene expression profile.
About Certis Oncology Solutions
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company’s product is Oncology Intelligence® — highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials.
Since its founding in 2016, Certis has offered personalized functional testing to help inform individual cancer treatment decisions, an approach gaining wide support from cancer researchers and oncology clinicians worldwide. Using our patent-pending artificial intelligence/machine learning platform and more clinically relevant, patient-derived tumor models, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.
For more information about Certis, visit www.certisoncology.com.
MEDIA CONTACT
Certis Oncology Solutions
Kristein King
kking@certisoncology.com
573-818-4528